Episode 17 Debunked: Are Big Pharmaceuticals ready for the impact of Trump administration’s health policies?
Changes in the Trump administration’s health care policy have sparked great concerns about their short-term and long-term consequences. In their monthly discussions, debunked podcast host host news editor Arundhati Parmar and managing partner of Health Innovation Pitch highlighted significant cuts in medical research grants, changes to the CDC vaccine committee and the burden that could shift to: the burden of big pharma companies.
The moderator also called for strong opposition to these cuts, a letter signed by NIH workers to NIH Director Jay Bhattacharya. A recent article by Medcity News highlighted some drama. NIH workers condemned the actions in a letter to Bhattacharya on June 9 and said they were “saving life-saving research significantly less.” Criticism letter: ended hundreds of funding for scientific and biomedical research; fired more than 1,000 employees this year; and transferred final funds to overseas partner agencies, current and former NIH workers said it would harm research on rare cancers and infectious diseases, as well as research aimed at minimizing tobacco use and related chronic diseases, among other areas.
Another topic on the podcast is the decision of Secretary of Health and Human Services Robert Kennedy Jr. to aim for the Centers for Gut Disease Control and Prevention’s Vaccine Advisory Group and replace members with an anti-VAX stance.
Samir noted that the result of Medicaid cuts is that big pharmaceutical companies may bear the burden of early research and development previously subsidized by the federal government.
“The biggest thing people don't realize is that the government funded early research and development,” Samir said. “These capabilities would be hampered without federal support.”
Check out the full Debunk Podcast below!
